Skip to main content

Table 2 Summary of plasma remoglifozin etabonate pharmacokinetic parameters in healthy subjects a,b

From: First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

Remogliflozin etabonate dose

20 mg

50 mg

150 mg

500 mg

1000 mg

AUC (0–∞) (ng•h/mL)

NQc

3.70 (46)d

9.77 (48)d

36.8 (67)e

126 (44)f

AUC (0–t) (ng.h/mL)

1.61 (67) g

3.56 (56)

9.51 (42)

35.4 (62)

107 (53)

C max (ng/mL)

1.89 (78)

4.98 (61)

17.6 (48)

41.6 (81)

144 (59)

T max (h)

0.625

0.625

0.515

1.25

0.625

0.33-2.03

0.17-1.50

0.17-1.50

0.33-2.50

0.33-2.50

T ½ (h)

NQc

0.353 (56)d

0.256 (35)d

0.263e (27)

0.707f (56)

  1. a. Geometric mean and CV% except for Tmax (median and range).
  2. b. n = 8 unless otherwise specified.
  3. c. NQ, not quantifiable because concentrations at later time points were below the limit of quantification.
  4. d. n = 6.
  5. e. n = 4.
  6. f. n = 7.
  7. g. n = 5.